Medicine - Hematology, Oncology, Transplant

Medicine & Life Sciences

1. Cell Transplantation 100%
2. Graft vs Host Disease 95%
3. Transplants 80%
4. Bone Marrow 74%
5. Neoplasms 65%
6. Survival 65%
7. Natural Killer Cells 63%
8. Breast Neoplasms 60%
9. Transplantation 58%
10. Allogeneic Cells 58%
11. Bone Marrow Transplantation 50%
12. Therapeutics 50%
13. Unrelated Donors 49%
14. Acute Myeloid Leukemia 48%
15. Tissue Donors 47%
16. Leukemia 45%
17. Sickle Cell Anemia 39%
18. Fetal Blood 38%
19. Recurrence 37%
20. Drug Therapy 36%
21. Prostatic Neoplasms 36%
22. Hematopoietic Stem Cell Transplantation 33%
23. Homologous Transplantation 30%
24. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 28%
25. Confidence Intervals 27%
26. Precursor Cell Lymphoblastic Leukemia-Lymphoma 25%
27. T-Lymphocytes 25%
28. Mortality 25%
29. Castration 22%
30. Non-Hodgkin's Lymphoma 22%
31. Myelodysplastic Syndromes 22%
32. Siblings 22%
33. Non-Small Cell Lung Carcinoma 21%
34. Clinical Trials 21%
35. Neutrophils 20%
36. Genes 19%
37. Immunotherapy 19%
38. Stem Cells 19%
39. Cyclophosphamide 18%
40. Lymphoma 18%
41. Progression-Free Survival 18%
42. Survivors 18%
43. Progesterone Receptors 18%
44. Hematopoietic Stem Cells 18%
45. Granulocytes 17%
46. Stem Cell Transplantation 17%
47. Hematologic Neoplasms 17%
48. Hodgkin Disease 17%
49. Incidence 16%
50. Lymphocytes 16%
51. In Vitro Techniques 16%
52. Biomarkers 15%
53. Proteins 15%
54. Somatomedins 15%
55. Growth 14%
56. Multiple Myeloma 14%
57. Infections 14%
58. Cell Line 14%
59. Prednisone 14%
60. Ligands 14%
61. Autologous Transplantation 14%
62. Heme 13%
63. Interleukin-15 13%
64. Population 13%
65. Hemophilia A 13%
66. Cell- and Tissue-Based Therapy 13%
67. Erythrocytes 13%
68. Neoplasm Metastasis 13%
69. Mutation 12%
70. KIR Receptors 12%
71. Interleukin-2 12%
72. Cancer Survivors 12%
73. Human Embryonic Stem Cells 12%
74. Endothelium 12%
75. Disease-Free Survival 12%
76. Blood Platelets 12%
77. Whole-Body Irradiation 12%
78. Cytokines 12%
79. Insulin-Like Growth Factor I 12%
80. Safety 11%
81. Blood Cells 11%
82. Protein-Tyrosine Kinases 11%
83. Cytomegalovirus 11%
84. Transplant Recipients 11%
85. Melanoma 11%
86. Antibodies 11%
87. Phenotype 11%
88. Mesothelioma 11%
89. Lung 10%
90. Peripheral Blood Stem Cells 10%
91. Gene Expression 10%
92. Lung Neoplasms 10%
93. Inflammation 10%
94. Phosphorylation 10%
95. Malignant Mesothelioma 9%
96. IGF Type 1 Receptor 9%
97. Serum 9%
98. Lymphoma, Large B-Cell, Diffuse 9%
99. Chimeric Antigen Receptors 9%